Operations
One tracks the effectiveness of COVID-19 drug therapies and the other pays for counseling to slow the spread of the virus.
A new report by HHS Secretary Alex Azar is calling for congressional action to combat surprise billing and to promote price transparency.
The top 10 COVID-19 medications have seen a combined spend increase of $200 million, with big increases in March and April.
This data confirms the COVID-19 pandemic is disproportionately affecting racial and ethnic minorities.
The rankings were determined in part by rating hospitals in 10 different procedures and conditions.
Industry groups said the funds are necessary to ensure that hospitals can continue to effectively respond to the pandemic.
In March there was a 35% decrease in weekly hospitalizations and a 45% decrease in weekly hospitalizations not related to COVID-19.
Even upticks in COVID-19 patients haven't made up for the revenue losses, since reimbursement for those services is comparatively slim.
Data from S&P Global Market Intelligence shows a decline in M&A value in Q2, which can be attributed to the pandemic.
Cigna received the highest marks for its efforts toward driving for value, while UnitedHealthcare ranked lowest.